Back to top

Analyst Blog

Boston Scientific Corporation (BSX - Analyst Report) recently revealed that it has received CE Mark approval and is proceeding with the full European market launch of the Ranger Paclitaxel-Coated PTA Balloon Catheter.

According to Boston Scientific, this new and advanced Drug-Coated Balloon (DCB) catheter will enrich the company’s portfolio of peripheral vascular disease products besides strengthening the company’s foothold in Europe.

The Ranger DCB is an additional option for the treatment of peripheral artery disease (PAD). It delivers an anti-stenotic drug to the unhealthy vascular tissue while leaving behind no permanent implant. Further, it offers a radical option to treat both above-the-knee and below-the-knee lesions.

According to a reliable source, in using traditional technologies, physicians end up losing a significant portion of drug coating during the handling, insertion and placement of the device. The Ranger DCB is so designed as to reduce pertinent drug loss while optimizing both deliverability and the absorption of the drug in the targeted tissue.

Notably, PAD is a circulatory disorder resulting from a build-up of plaque in one or more arteries, most often in the legs. With the aggravation of PAD in a patient, plaque accumulation may reduce blood flow through the arteries significantly. This may result in pain and increasing disability with severe cases even leading to amputation of the affected limb.

In recent times, PAD has become a major cause of worry all over the world. As per recent data, at present, 12−14% of the general population is affected by PAD.  Boston Scientific, which has become a forerunner with its advanced drug-eluting technologies, is thus upbeat about the recent European approval of the Ranger DCB which it expects as having the potential to capture significant market share in this geography.

The Peripheral Interventions (PI) business of Boston Scientific has continuously delivered above-market growth in the last few quarters driven by strong international and emerging market performance. According to the company, this consistent success is driven by its leadership positions in balloons, stents and interventional oncology.

Growth in the U.S. is also encouraging on the back of the Epic stent (a self-extending Nitinol stent ideal for the iliac's, launched in 2012), the carotid wall stent, and the direction micro-catheter for the delivery of diagnostic or therapeutic material, which was launched in the fourth quarter of 2013.

Other Stocks to Consider

Boston Scientific currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical sector that look promising at the moment are Masimo Corp. (MASI - Analyst Report), Hologic Inc. (HOLX - Analyst Report) and Intuitive Surgical, Inc. (ISRG - Analyst Report). While MASI sports a Zacks Rank #1 (Strong Buy), the other two stocks carry a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.